{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:40:25Z","timestamp":1785526825888,"version":"3.56.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-026-05163-2","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:53:20Z","timestamp":1784696000000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient-reported outcomes in Chinese patients with AQP4-IgG\u2013positive neuromyelitis optica spectrum disorder on inebilizumab therapy: a cross-sectional study"],"prefix":"10.1186","volume":"26","author":[{"given":"Hexiang","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengdi","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"issue":"2","key":"5163_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177\u201389.","journal-title":"Neurology"},{"issue":"11","key":"5163_CR2","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","volume":"73","author":"V Damato","year":"2016","unstructured":"Damato V, Evoli A, Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol. 2016;73(11):1342\u20138.","journal-title":"JAMA Neurol"},{"issue":"9","key":"5163_CR3","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","volume":"264","author":"Z Nikoo","year":"2017","unstructured":"Nikoo Z, Badihian S, Shaygannejad V, Asgari N, Ashtari F. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol. 2017;264(9):2003\u20139.","journal-title":"J Neurol"},{"issue":"1","key":"5163_CR4","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","volume":"18","author":"E Carnero Contentti","year":"2021","unstructured":"Carnero Contentti E, Correale J. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. J Neuroinflamm. 2021;18(1):208.","journal-title":"J Neuroinflamm"},{"issue":"1","key":"5163_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S1474-4422(20)30392-6","volume":"20","author":"M Levy","year":"2021","unstructured":"Levy M, Fujihara K, Palace J. New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol. 2021;20(1):60\u20137.","journal-title":"Lancet Neurol"},{"issue":"10206","key":"5163_CR6","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","volume":"394","author":"BAC Cree","year":"2019","unstructured":"Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E. N-MOmentum study investigators. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial. Lancet. 2019;394(10206):1352\u201363.","journal-title":"Lancet"},{"issue":"6","key":"5163_CR7","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/S1474-4422(24)00077-2","volume":"23","author":"BAC Cree","year":"2024","unstructured":"Cree BAC, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, She D, Rees W, Smith M, Cimbora D, Katz E, Bennett JL. N-MOmentum study investigators. Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial. Lancet Neurol. 2024;23(6):588\u2013602.","journal-title":"Lancet Neurol"},{"issue":"6","key":"5163_CR8","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware JE Jr, Sherbourne CD. The MOS 36\u2013Item Short\u2013Form Health Survey (SF\u201336). I. Conceptual framework and item selection. Med Care. 1992;30(6):473\u201383.","journal-title":"Med Care"},{"key":"5163_CR9","unstructured":"Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Boston: The Health Institute, New England Medical Center; 1993."},{"key":"5163_CR10","unstructured":"Likert R. A technique for the measurement of attitudes. Archives of Psychology. 1932;22(140):1\u201355."},{"issue":"9","key":"5163_CR11","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1001\/archneurol.2012.314","volume":"69","author":"MA Mealy","year":"2012","unstructured":"Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol. 2012;69(9):1176\u201380.","journal-title":"Arch Neurol"},{"issue":"6","key":"5163_CR12","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1002\/ana.26623","volume":"93","author":"HX Yin","year":"2023","unstructured":"Yin HX, Wang YJ, Liu MG, Zhang DD, Ren HT, Mao ZF, Zhang Y, Peng B, Cui LY, Xu Y. Aquaporin-4 antibody dynamics and relapse risk in seropositive neuromyelitis Optica Spectrum disorder treated with immunosuppressants. Ann Neurol. 2023;93(6):1069\u201381.","journal-title":"Ann Neurol"},{"issue":"7","key":"5163_CR13","first-page":"687","volume":"58","author":"Chinese Society of Neuroimmunology","year":"2025","unstructured":"Chinese Society of Neuroimmunology. Chinese guidelines for diagnosis and treatment of neuromyelitis optica spectrum disorders (2025 edition). Chin J Neurol. 2025;58(7):687\u2013703.","journal-title":"Chin J Neurol"},{"issue":"7","key":"5163_CR14","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40263-025-01191-7","volume":"39","author":"G Novi","year":"2025","unstructured":"Novi G, Bovis F, Sciolla C, Frau J, Minetti M, Napoli F, Vianello M, Greco G, Sechi E, Bellomo A, Garelli P, Novi, et al. CNS Drugs. 2025;39(7):693\u2013705.","journal-title":"CNS Drugs"},{"issue":"2","key":"5163_CR15","doi-asserted-by":"publisher","first-page":"e200536","DOI":"10.1212\/NXI.0000000000200536","volume":"13","author":"PA Bilodeau","year":"2026","unstructured":"Bilodeau PA, Wruble Clark M, Ganguly A, Harowitz JB, Mahler JV, Jiang M, Narasimhan SS, Pua DK, Healy BC, Mateen FJ, Levy M. Real-World Efficacy and Safety of Neuromyelitis Optica Spectrum Disorder Disease-Modifying Treatments. Neurol Neuroimmunol Neuroinflammation. 2026;13(2):e200536.","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"3","key":"5163_CR16","doi-asserted-by":"publisher","first-page":"e70545","DOI":"10.1111\/ene.70545","volume":"33","author":"Y Cui","year":"2026","unstructured":"Cui Y, Yu Z, Cong H, Zhang H, Shi Y, Guo A, Li Y, Jia D, Zhang C, Shi K, Shi FD. Efficacy and Safety of Rituximab Versus Inebilizumab in Patients With Neuromyelitis Optica Spectrum Disorder: A Dual-Center, Real\u2010World Cohort Study. Eur J Neurol. 2026;33(3):e70545.","journal-title":"Eur J Neurol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-05163-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-05163-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-05163-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:04:12Z","timestamp":1785521052000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-05163-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5163"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-05163-2","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki. As this was a questionnaire-based survey with minimal risk to participants, and all data were collected anonymously and in a de-identified manner without any personal identifiers, ethical approval and written informed consent were waived by the Ethics Review Committee of Peking Union Medical College Hospital, given the observational, non-interventional, and low-risk nature of the study. Verbal informed consent was obtained from all participants prior to questionnaire completion.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"484"}}